IDH1 and glioblastoma: Emerging biological studies has to some extent improved diagnostic and therapeutic strategies for IDH-wildtype GBM; however, there has been no breakthrough, owing to both tumor heterogeneity and a limited understanding of pathogenesis of this type of GBM.